REFERENCES
- Sessa C, Shapiro GI, Bhalla KN,Britten C, Jacks KS, Mita M,First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors. Clin Cancer Res 2013;19:3671–3680.
- Drysdale MJ,Brough PA,Massey A,Jensen MR, Schoepfer J. Targeting Hsp90 for the treatment of cancer. Curr Opin Drug Discov Devel 2006;9:483–495.
- Burkitt M,Magee C,O'Connor D,Campbell F, Cornford P, Greenhalf W. Potentiation of chemotherapeutics by the Hsp90 antagonist geldanamycin requires a steady serum condition. Mol Carcinog 2007;46:466–475.
- Declaration of Helsinki. Available from: www.wma.net/ e/ethicsunit/helsinki.htm: World Medical Association, Ethics Unit 2007.
- Eisenhauer EA,Therasse P,Bogaerts J,Schwartz LH, Sargent D, Ford R,New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–247.
- NCI Common Terminology Criteria for Adverse Events (CTCAE) v.4. In. Available from http://evs.nci.gov/ftp1/CTCAE/ about/html: National Cancer Institute 2010.
- Banerji U,O'Donnell A,Scurr M,Pacey S, Stapleton S, Asad Y,Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005;23:4152–4161.
- Goldman JW,Raju RN,Gordon GA,El-Hariry I, Teofilivici F, Vukovic VM,A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies. BMC Cancer 2013;13:152.
- Bauer T,Infante J,Ramanathan G,Sachdev J, Burris H, Hinson J,Results of two phase I dose escalation studies of the oral heat shock protein 90 (Hsp90) inhibitor SNX-5422. In J Clin Oncol 2013;31 ( suppl; abstr 2617).
- Modi S,Sugarman S,Stopeck A,Stopeck H, Linden W, Kersey K,Phase II trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC). In J Clin Oncol (Meeting Abstracts) May 2008;26(15):1027.
- Vaishampayan UN,Burger AM,Sausville EA,Heilbrun LK, Li J, Horiba MN,Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin. Clin Cancer Res 2010;16:3795–3804.
- Richardson PG,Chanan-Khan AA,Alsina M,Albitar M, Berman D, Messina M,Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study. Br J Haematol 2010;150:438–445.
- Pacey S,Gore M,Chao D,Banerji U, Larkin J, Sarker S,A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. Invest New Drugs 2012;30:341–349.
- Neckers L,Workman P. Hsp90 Molecular chaperone inhibitors: are we there yet?. Clinical Cancer Research 2012;18:64–76.
- Ono N,Yamazaki T,Tsukaguchi T,Fujii T, Sakata K, Suda A,Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer. Cancer Sci 2013;104:1346–1352.
- Johnson M,Hart E,Rademaker A,Weitner B, Urman A, Simm H,A phase II study of HSP90 inhibitor AUY922 and erlotinib (E) for patients (pts) with EGFR-mutant lung cancer and acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR TKIs). In J Clin Oncol 2013;31(suppl; abstr 8036).